ArticleExpert review of ophthalmology2010
Pharmaceutical intervention for myopia control.
Article in Expert review of ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 84 citations in OpenAlex.
- Bifocal & Atropine in Myopia Study: Baseline Data and Methods.Optometry and vision science : official publication of the American Academy of Optometry · 2019Trial
- The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth.Heliyon · 2024Article
- A Clinical Study of the Impact of Soft Contact Lenses on the Progression of Myopia in Young Patients.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- An Updated Meta-Analysis of Controlling Myopia with Auricular Acupoint Stimulation.Medical acupuncture · 2021Article
- Article
- Higher HbA1c may reduce axial length elongation in myopic children: a comparison cohort study.Acta diabetologica · 2021Article
- Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2021Article
- Association of Myopia in Elementary School Students in Jiaojiang District, Taizhou City, China.Journal of ophthalmology · 2021Article
- Biological Mechanisms of Atropine Control of Myopia.Eye & contact lens · 2020Review
- Regulatory roles of differentially expressed MicroRNAs in metabolic processes in negative Lens-induced myopia Guinea pigs.BMC genomics · 2020Article
- Biometric evaluation of myopic eyes without posterior staphyloma: disproportionate ocular growth.International ophthalmology · 2018Article
- Gene expression in response to optical defocus of opposite signs reveals bidirectional mechanism of visually guided eye growth.PLoS biology · 2018Article
- Preventing Myopia.Deutsches Arzteblatt international · 2017Article
- α-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: A pilot study.Molecular vision · 2017Article
- [Biological mechanisms of myopia].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Review
- Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study.BMC ophthalmology · 2016Article
- The effect of intravitreal injection of vehicle solutions on form deprivation myopia in tree shrews.Experimental eye research · 2016Article
- Molecular and Biochemical Aspects of the Retina on Refraction.Progress in molecular biology and translational science · 2015Review
- Myopia in young adults is inversely related to an objective marker of ocular sun exposure: the Western Australian Raine cohort study.American journal of ophthalmology · 2014Article
- Arachnoid cyst accompanied by proptosis and unilateral high myopia.International ophthalmology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Myopia is the result of a mismatch between the optical power and the length of the eye, with the latter being too long. Driving the research in this field is the need to develop myopia treatments that can limit axial elongation. When axial elongation is excessive, as in high myopia, there is an increased risk of visual impairment and blindness due to ensuing pathologies such as retinal detachments. This article covers both clinical studies involving myopic children, and studies involving animal models for myopia. Atropine, a nonselective muscarinic antagonist, has been studied most extensively in both contexts. Because it remains the only drug used in a clinical setting, it is a major focus of the first part of this article, which also covers the many shortcomings of topical ophthalmic atropine. The second part of this article focuses on in vitro and animal-based drug studies, which encompass a range of drug targets including the retina, retinal pigment epithelium and sclera. While the latter studies have contributed to a better understanding of how eye growth is regulated, no new antimyopia drug treatments have reached the clinical setting. Less conservative approaches in research, and in particular, the exploration of new bioengineering approaches for drug delivery, are needed to advance this field.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.